Heat-stable ritonavir approved, ending treatment stranglehold for people living with HIV/AIDSread more
Make It Happen Campaign Update: UNITAID Board still discussing finer details of the Patent Pool Entity read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
U.S. health care legislation could limit access read more
MSF responds to World Health Organization’s new HIV treatment guidelines read more
MSF sends letter to EU Ministers of Health regarding antibiotic resistance read more
 |
 |
|
 |
MSF urges new approach to TB drug development:
MSF has joined international experts in calling for new drug trials that could speed up the delivery of newer and better medicines for patients suffering from drug-resistant TB. The proposed trials are outlined in a scientific paper published by PLoS to coincide with Union World TB conference in Cape Town in November 2007.
Currently, the main strategy in TB drug development is to develop a completely new regimen of TB drugs. While this is an important objective, it will not be realised for at least a decade.
That is too long to wait for patients suffering from drug-resistant TB at present and the nearly half a million new cases that emerge every year. Current treatment for drug-resistant TB is very long (up to two years), ineffective and produces often intolerable side effects.
A further PLoS paper sets out the urgent case for building capacity to conduct clinical trials in those countries where many drug-resistant TB patients live.
The PLoS papers arose out of discussions held during a conference hosted by MSF in New York to address the gaps in the TB drugs pipeline.
Read more
PLoS Paper on Randomized drug trials 
MSF Clinical Officer Olesi Ellemani Pasulani's reflections on AIDS treatment in Malawi
Living with MDR TB: 'Expert Client' Nonkululeko Mamba's Story
MDR TB Treatment in Cambodia: A Catalyst for Change
